PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL
Shenmiao Yang,
Haiwen Huang,
Keshu Zhou,
Xielan Zhao,
Yan-Qiu Han#,
Lindong LI,
Anna Butturini,
Yiqiu Wang,
Xiaofeng Liu,
Peiqiong Lai,
Jianyong LI
Affiliations
Shenmiao Yang
1 Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China
Haiwen Huang
2 The First Hospital of Soochow University, Suzhou
Keshu Zhou
3 Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
Xielan Zhao
4 Xiangya Hospital Central South University, Xiangya, China
Yan-Qiu Han#
5 The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
Lindong LI
6 AstraZeneca, Shanghai, China
Anna Butturini
7 AstraZeneca, South San Francisco, United States
Yiqiu Wang
6 AstraZeneca, Shanghai, China
Xiaofeng Liu
6 AstraZeneca, Shanghai, China
Peiqiong Lai
6 AstraZeneca, Shanghai, China
Jianyong LI
8 The First Affiliated Hospital With Nanjing Medical University, Nanjing, China
